This measure captures the proportion of ischemic stroke patients who had antithrombotic therapy administered by end of hospital day two (with the day of arrival being day 1).
This measure is a part of a set of eight nationally implemented measures that address stroke care (STK-1: Venous Thromboembolism (VTE) Prophylaxis, STK-2: Discharged on Antithrombotic Therapy, STK-3: Anticoagulation Therapy for Atrial Fibrillation/Flutter, STK-4: Thrombolytic Therapy, STK-6: Discharged on Statin Medication, STK-8: Stroke Education, and STK-10: Assessed for Rehabilitation) that are used in The Joint Commission’s hospital accreditation and Disease-Specific Care certification programs.
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.9 Care Setting1.20 Testing Data Sources
-
1.14 Numerator
Ischemic stroke patients who had antithrombotic therapy administered by
end of hospital day two.
-
1.15 Denominator
Ischemic stroke patients
-
Exclusions
• Less than 18 years of age
• Duration of Stay < 2 days
• Length of Stay > 120 days
• Comfort measures only documented on the day of or day after hospital arrival
• Enrolled in clinical trials related to stroke
• Admitted for elective carotid intervention
• IV OR IA thrombolytic therapy administered at this hospital or within 24 hours prior to arrival
• Documented reason for not administering antithrombotic therapy by end of hospital day 2
-
Most Recent Endorsement ActivityEndorsed with Reserve Status Neurology Project 2015-2016Initial EndorsementLast Updated
-
StewardThe Joint CommissionSteward Organization POC EmailSteward Organization Copyright
No royalty or use fee is required for copying or reprinting this manual, but the following are required as a condition of usage: 1) disclosure that the Specifications Manual is periodically updated, and that the version being copied or reprinted may not be up-to-date when used unless the copier or printer has verified the version to be up-to-date and affirms that, and 2) users participating in Joint Commission accreditation, including ORYX® vendors, are required to update their software and associated documentation based on the published manual production timelines.
-
-
-
Risk Adjustment
-
-
-
6.1.2 Current or Planned Use(s)
-